[1]郑艳芳,郭军霞,张永春.原发性高血压合并阵发性心房颤动的危险因素分析[J].医学信息,2021,34(22):51-53.[doi:10.3969/j.issn.1006-1959.2021.22.014]
　ZHENG Yan-fang,GUO Jun-xia,ZHANG Yong-chun.Risk Factors Analysis of Essential Hypertension Complicated with Paroxysmal Atrial Fibrillation[J].Medical Information,2021,34(22):51-53.[doi:10.3969/j.issn.1006-1959.2021.22.014]
点击复制

原发性高血压合并阵发性心房颤动的危险因素分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年22期
页码:
51-53
栏目:
论著
出版日期:
2021-11-15

文章信息/Info

Title:
Risk Factors Analysis of Essential Hypertension Complicated with Paroxysmal Atrial Fibrillation
文章编号:
1006-1959（2021）22-0051-03
作者:
郑艳芳; 郭军霞; 张永春
（新乡医学院第一附属医院心血管内科二病区，河南 新乡 453000）
Author(s):
ZHENG Yan-fang; GUO Jun-xia; ZHANG Yong-chun
(Department of Cardiology,the First Affiliated Hospital of Xinxiang Medical College,Xinxiang 453000,Henan,China)
关键词:
原发性高血压; 阵发性心房颤动; 左房内径
Keywords:
Essential hypertension; Paroxysmal atrial fibrillation; Left atrial diameter
分类号:
R541.7+5
DOI:
10.3969/j.issn.1006-1959.2021.22.014
文献标志码:
A
摘要:
目的 分析原发性高血压合并阵发性心房颤动的危险因素。方法 选取2018年9月-2020年10月我院收治的原发性高血压患者422例，根据是否合并有阵发性心房颤动分为高血压病组和高血压合并阵发性心房颤动组，分析高血压合并阵发性心房颤动的危险因素。结果 422例原发性高血压中合并阵发性心房颤动者109例。高血压病组和高血压合并阵发性心房颤动组性别、吸烟史、饮酒史、糖尿病史、体质指数、甘油三酯、同型半胱氨酸比较，差异均无统计学意义（P＞0.05）；两组年龄、肌酐、尿酸、总胆固醇、高密度脂蛋白、低密度脂蛋白、左房内径、左室后壁厚度、室间隔厚度、左室舒张末期内径、左室收缩末期内径、左室射血分数比较，差异有统计学意义（P＜0.05）。二元Logistic回归分析显示，年龄、尿酸、左房内径、室间隔厚度增高是高血压合并阵发性心房颤动的危险因素，左室收缩末期内径、左室射血分数、低密度脂蛋白增高是高血压合并阵发性心房颤动的保护因素。ROC曲线分析显示，联合因子曲线下面积为0.887。结论 年龄及左房内径对原发性高血压患者发生阵发性心房颤动有一定的预测价值。
Abstract:
Objective To analyze the risk factors of primary hypertension complicated with paroxysmal atrial fibrillation.Methods A total of 422 patients with essential hypertension admitted to our hospital from September 2018 to October 2020 were selected and divided into hypertension group and hypertension combined with paroxysmal atrial fibrillation group according to whether they had paroxysmal atrial fibrillation. The risk factors of hypertension combined with paroxysmal atrial fibrillation were analyzed.Results There were 109 patients with paroxysmal atrial fibrillation in 422 patients with essential hypertension. There was no significant difference in sex, smoking history, drinking history, diabetes history, body mass index, triglyceride and homocysteine between hypertension group and hypertension with paroxysmal atrial fibrillation group (P>0.05); there were significant differences in age, creatinine, uric acid, total cholesterol, high density lipoprotein, low density lipoprotein, left atrial diameter, left ventricular posterior wall thickness, ventricular septal thickness, left ventricular end-diastolic diameter, left ventricular end-systolic diameter and left ventricular ejection fraction between the two groups (P<0.05). Binary Logistic regression analysis showed that age, uric acid, left atrial diameter and ventricular septal thickness were risk factors for hypertension complicated with paroxysmal atrial fibrillation, and left ventricular end systolic diameter, left ventricular ejection fraction and low density lipoprotein were protective factors for hypertension complicated with paroxysmal atrial fibrillation. ROC curve analysis showed that the area under the joint factor curve was 0.887.Conclusion Age and left atrial diameter have certain predictive value for paroxysmal atrial fibrillation in patients with essential hypertension.

参考文献/References:

[1]Joseph PG,Healey JS,Raina P,et al.Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals[J].Cardiovasc Res,2021,117(6):1523-1531.[2]Zhao LQ,Liu SW.Atrial fibrillation in essential hypertension: an issue of concern[J].J Cardiovasc Med (Hagerstown),2014,15(2):100-106.[3]Kerr CR,Humphries KH,Talajic M,et al.Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation[J].Am Heart J,2005,149(3):489-496.[4]Guo Y,Tian Y,Wang H,et al.Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation[J].Chest,2015,147(1):109-119.[5]Koshiyama M,Tamaki K,Ohsawa M.Age-specific incidence rates of atrial fibrillation and risk factors for the future development of atrial fibrillation in the Japanese general population[J].J Cardiol,2021,77(1):88-92.[6]Kawasoe S,Kubozono T,Yoshifuku S,et al.Uric Acid Level and New-Onset Atrial Fibrillation in the Japanese General Population- Longitudinal Study[J].Circ J,2018,83(1):156-163.[7]Lopez FL,Agarwal SK,Maclehose RF,et al.Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study[J].Circ Arrhythm Electrophysiol,2012,5(1):155-162.[8]Harrison SL,Lane DA,Banach M,et al.Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGRAM2015 study[J].Atherosclerosis,2020(312):16-22.[9]Iguchi Y,Kimura K,Shibazaki K,et al.Annual incidence of atrial fibrillation and related factors in adults[J].Am J Cardiol,2010,106(8):1129-1133.[10]Marrouche NF,Wilber D,Hindricks G,et al.Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study[J].JAMA,2014,311(5):498-506.

相似文献/References:

[1]段淑婷,王义围,王兆鹏.高血压病合并糖调节受损患者血压变异性的相关研究[J].医学信息,2018,31(05):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
　DUAN Shu-ting,WANG Yi-wei,WANG Zhao-peng.Study on Blood Pressure Variability in Patients with Hypertension Complicated with Impaired Glucose Regulation[J].Medical Information,2018,31(22):11.[doi:10.3969/j.issn.1006-1959.2018.05.004]
[2]熊依良.奥美沙坦酯氢氯噻嗪片治疗轻中度原发性高血压的疗效及安全性分析[J].医学信息,2018,31(19):142.[doi:10.3969/j.issn.1006-1959.2018.19.043]
　XIONG Yi-liang.Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Tablets in the Treatment of Mild to Moderate Essential Hypertension[J].Medical Information,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.19.043]
[3]李信明,刘春梅,任正强,等.供需平衡视角下原发性高血压的病机与防治[J].医学信息,2018,31(19):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
　LI Xin-Ming,LIU Chun-Mei,REN Zheng-Qiang,et al.Pathogenesis and Prevention of Essential Hypertension from the Perspective of Supply and Demand Balance[J].Medical Information,2018,31(22):182.[doi:10.3969/j.issn.1006-1959.2018.19.058]
[4]穆大明.厄贝沙坦氢氯噻嗪与福辛普利治疗原发性高血压的疗效观察[J].医学信息,2019,32(03):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
　MU Da-ming.Efficacy of Irbesartan Hydrochlorothiazide and Fosinopril in the Treatment of Essential Hypertension[J].Medical Information,2019,32(22):151.[doi:10.3969/j.issn.1006-1959.2019.03.049]
[5]潘建鑫.高血压患者血小板/淋巴细胞比值与颈动脉粥样硬化的相关性分析[J].医学信息,2020,33(05):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
　Pan Jianxin.Correlation analysis of platelet/lymphocyte ratio and carotid atherosclerosisin patients with primary hypertension[J].Medical Information,2020,33(22):77.[doi:10.3969/j.issn.1006-1959.2020.05.023]
[6]谢祥红.AngⅡ、ET-1对高血压患者病情发生发展的影响[J].医学信息,2020,33(16):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
　XIE Xiang-hong.Effects of AngⅡ and ET-1 on the Occurrence and Development of Hypertension Patients[J].Medical Information,2020,33(22):75.[doi:10.3969/j.issn.1006-1959.2020.16.023]
[7]刘 柳,吕风华.原发性高血压患者脉压与左心室肥厚及射血分数保留的心衰的相关性[J].医学信息,2021,34(01):112.[doi:10.3969/j.issn.1006-1959.2021.01.029]
　LIU Liu,LYU Feng-hua.Correlation of Pulse Pressure with Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction in Patients with Essential Hypertension[J].Medical Information,2021,34(22):112.[doi:10.3969/j.issn.1006-1959.2021.01.029]
[8]魏 炜.奥美沙坦酯和坎地沙坦酯治疗原发性高血压的效果比较[J].医学信息,2021,34(14):160.[doi:10.3969/j.issn.1006-1959.2021.14.045]
　WEI Wei.Comparison of the Effects of Olmesartan Medoxomil and Candesartan Cilexetil in the Treatment of Essential Hypertension[J].Medical Information,2021,34(22):160.[doi:10.3969/j.issn.1006-1959.2021.14.045]
[9]谭碧峰,黄友良,凌 莎,等.基于有序Logistic回归模型的H型高血压疗效影响因素研究[J].医学信息,2022,35(05):69.[doi:10.3969/j.issn.1006-1959.2022.05.017]
　TAN Bi-feng,HUANG You-liang,LING Sha,et al.Analysis of Influencing Factors on the Efficacy of H-type hypertension Based on Ordinal Logistic Regression Model[J].Medical Information,2022,35(22):69.[doi:10.3969/j.issn.1006-1959.2022.05.017]
[10]张 伟.动态血压监测不同剂型硝苯地平在原发性高血压患者中的治疗效果[J].医学信息,2022,35(10):152.[doi:10.3969/j.issn.1006-1959.2022.10.038]
　ZHANG Wei.Effect of Different Dosage Forms of Nifedipine on Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension[J].Medical Information,2022,35(22):152.[doi:10.3969/j.issn.1006-1959.2022.10.038]

更新日期/Last Update: 1900-01-01